OBJECTIVE: Although hyperuricaemia and gout are associated with an increased future risk of diabetes, diabetes may reduce the future risk of gout through the uricosuric effect of glycosuria or the impaired inflammatory response. The present work evaluates the impact of diabetes on the future risk of developing gout. METHODS: A case-control study nested in a UK general practice database (the health improvement network) was conducted by identifying all incident cases of gout (N=24 768) and randomly sampling 50,000 controls who were 20-89 years between 2000 and 2007. The independent effect of type 1 and type 2 diabetes on the development of incident gout was examined. RESULTS: After adjusting for age, sex, body mass index, general practitioner visits, smoking, alcohol intake, ischaemic heart disease and presence of cardiovascular risk factors, the RR for incident gout among patients with diabetes, as compared with individuals with no diabetes was 0.67 (95% CI 0.63 to 0.71). The multivariate RRs with the duration of diabetes of 0-3, 4-9 and ≥ 10 years were 0.81 (95% CI 0.74 to 0.90), 0.67 (95% CI 0.61 to 0.73) and 0.52 (95% CI 0.46 to 0.58), respectively. The inverse association was stronger with type 1 diabetes than with type 2 diabetes (multivariate RR, 0.33 vs 0.69) and stronger among men than women (p value for interaction < 0.001). CONCLUSIONS: Individuals with diabetes are at a lower future risk of gout independent of other risk factors. These data provide support for a substantial role of the pathophysiology associated with diabetes against the risk of developing gout.
OBJECTIVE: Although hyperuricaemia and gout are associated with an increased future risk of diabetes, diabetes may reduce the future risk of gout through the uricosuric effect of glycosuria or the impaired inflammatory response. The present work evaluates the impact of diabetes on the future risk of developing gout. METHODS: A case-control study nested in a UK general practice database (the health improvement network) was conducted by identifying all incident cases of gout (N=24 768) and randomly sampling 50,000 controls who were 20-89 years between 2000 and 2007. The independent effect of type 1 and type 2 diabetes on the development of incident gout was examined. RESULTS: After adjusting for age, sex, body mass index, general practitioner visits, smoking, alcohol intake, ischaemic heart disease and presence of cardiovascular risk factors, the RR for incident gout among patients with diabetes, as compared with individuals with no diabetes was 0.67 (95% CI 0.63 to 0.71). The multivariate RRs with the duration of diabetes of 0-3, 4-9 and ≥ 10 years were 0.81 (95% CI 0.74 to 0.90), 0.67 (95% CI 0.61 to 0.73) and 0.52 (95% CI 0.46 to 0.58), respectively. The inverse association was stronger with type 1 diabetes than with type 2 diabetes (multivariate RR, 0.33 vs 0.69) and stronger among men than women (p value for interaction < 0.001). CONCLUSIONS: Individuals with diabetes are at a lower future risk of gout independent of other risk factors. These data provide support for a substantial role of the pathophysiology associated with diabetes against the risk of developing gout.
Authors: S C Cavalher-Machado; W Tavares de Lima; A S Damazo; V de Frias Carvalho; M A Martins; P M R e Silva; P Sannomiya Journal: Eur Respir J Date: 2004-10 Impact factor: 16.671
Authors: Renata C O Zanardo; José W M C Cruz; Luis L Martinez; Maria Ap de Oliveira; Zuleica B Fortes Journal: Eur J Pharmacol Date: 2003-10-08 Impact factor: 4.432
Authors: E L Massó González; S Johansson; M-A Wallander; L A García Rodríguez Journal: J Epidemiol Community Health Date: 2009-02-24 Impact factor: 3.710
Authors: Young Hee Rho; Na Lu; Christine E Peloquin; Ada Man; Yanyan Zhu; Yuqing Zhang; Hyon K Choi Journal: Ann Rheum Dis Date: 2014-10-02 Impact factor: 19.103
Authors: U Kiltz; R Alten; M Fleck; K Krüger; B Manger; U Müller-Ladner; H Nüßlein; M Reuss-Borst; A Schwarting; H Schulze-Koops; A Tausche; J Braun Journal: Z Rheumatol Date: 2016-08 Impact factor: 1.372
Authors: Stephen P Juraschek; Mara McAdams-Demarco; Edgar R Miller; Allan C Gelber; Janet W Maynard; James S Pankow; Hunter Young; Josef Coresh; Elizabeth Selvin Journal: Am J Epidemiol Date: 2014-01-12 Impact factor: 4.897
Authors: Petter Bjornstad; Janet K Snell-Bergeon; Kimberly McFann; R Paul Wadwa; Marian Rewers; Christopher J Rivard; Diana Jalal; Michel B Chonchol; Richard J Johnson; David M Maahs Journal: J Diabetes Complications Date: 2013-12-27 Impact factor: 2.852
Authors: Christian S Göbl; Latife Bozkurt; Johannes Lueck; Mona El-Samahi; Peter Grösser; Martin Clodi; Anton Luger; Alexandra Kautzky-Willer Journal: Wien Klin Wochenschr Date: 2012-10-16 Impact factor: 1.704